Persistence with Cholinesterase Inhibitor Treatment in Alzheimer's Disease
Can J Neurol Sci. 2013; 40: 623-624 EDITORIAL sample of individuals living in the community, who received an extensive evaluation by experts in a specialized clinic. Previous studies of ChEI persistence, including three from Canada [7] [8] [9] , yielded persistence rates between 57% and 69% at 6 months, and between 34% and 57% at 12 months. Many of these studies consisted of analysing administrative healthcare databases including several thousand patients. One French study showed a surprisingly high persistence rate at one year (96.4% per 100 persons-years), but the study sample consisted of patients diagnosed and treated in AD expert centers 10 . In previous studies, factors associated with increased persistence have included extended-release and transdermal formulations, the chronic disease score (an indicator of comorbidity based on the number and type of medications prescribed), higher functional performance, multiple concomitant medications including memantine, the number of physician visits and the number of hospitalisations in the previous year (Table) . Factors associated with decreased persistence include side effects, female gender, increasing age, lower MMSE score at initiation, concomitant anticholinergic medications, and having to pay for a significant proportion of the prescription cost. Hence, persistence seems to be facilitated by better tolerance (transdermal formulation), ease of use (extended-release formulation), "exposure" to the healthcare system (number of visits to the physician and of hospitalisations, higher chronic disease score), severity of the disease, use of concomitant medications, and reimbursement issues. A very important factor, which is not well captured in persistence studies, is setting realistic expectations with theses medications. In the study by Saleh et al, 10 out of 19 individuals discontinued ChEI because of "ineffectiveness of the drug". This can be difficult to assess after six months of treatment. As stated earlier, this class of medication does not alter progression of the disease, and provides modest symptomatic benefits. In many patients, these benefits are not clearly observable. Nevertheless, considering the neurodegenerative nature of the disease, stabilisation is an acceptable outcome of treatment. This element is essential, although sometimes difficult to convey to patients and their caregivers, as well as to prescribing physicians who are less familiar with these medications and their expected benefits. A simple guide to assess "satisfactory" response to ChEI during the first year of treatment is the following: stabilisation, improvement, or a deterioration of no more than 2 points on the MMSE, lack of significant functional deterioration, and absence of new behavioral symptoms 11 .
The optimal duration of treatment with ChEI is still a matter of controversy. Unfortunately, there are no randomized clinical trials beyond 12 months to guide this decision. There is some compelling evidence from observational data as to the long-term benefits of treatment, such as delaying nursing home placement 12 . Arguments for discontinuation of ChEI are often vague and subjective. In a clear effort to avoid arbitrary criteria (such as a cutoff on the MMSE or nursing home placement), the most recent CCCDTD has updated its guidelines on discontinuation of treatment 2 . Proposed recommendations for discontinuation include intolerable side effects that are convincingly related to ChEI, more rapid clinical deterioration with treatment, and progression to the severe stages of AD (Reisberg stage 7). In the absence of clearer recommendations, many experts would contend that long-term treatment of AD should be pursued as long as benefits are observed. These benefits, especially in a deteriorating patient, should be determined by an open discussion between the physician, healthcare personnel involved in the patient's care, the patient himself if possible, and caregivers. Table: Factors associated with persistence to cholinesteras inhibitor treatment
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